<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03069131</url>
  </required_header>
  <id_info>
    <org_study_id>ProPILA-Rifax</org_study_id>
    <nct_id>NCT03069131</nct_id>
  </id_info>
  <brief_title>Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites</brief_title>
  <acronym>ProPILARifax</acronym>
  <official_title>A Multicenter, Double-blind, Placebo-controlled Randomized Clinical Trial Comparing Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites : Using or Not Using Rifaximin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alfasigma S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>LC2 PHARMA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We wish to perform a multicenter, double-blind RCT with two parallel-group stratified on the
      center, comparing rifaximin to no rifaximin (placebo) for the primary prophylaxis of SBP in
      'severe' cirrhotic patients with large ascites. The primary outcome will be the 12-month
      survival.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>12 months</time_frame>
    <description>record of death whatever the cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality rate and mortality rate at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>survival during hospitalization and at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality rate and mortality rate at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>survival during hospitalization and at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of spontaneous bacterial peritonitis during follow-up</measure>
    <time_frame>12 months</time_frame>
    <description>Bacterial analysis of ascites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the other complications of liver cirrhosis during follow-up</measure>
    <time_frame>12 months</time_frame>
    <description>complications of liver cirrhosis : HE, gastrointestinal bleeding and hepatorenal syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient hospitalizations during follow-up</measure>
    <time_frame>12 months</time_frame>
    <description>number of days of hospitalization during 12 months of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative variations of IL-6 in serum between day 1 and day 30</measure>
    <time_frame>1 month</time_frame>
    <description>Dosage of IL-6 in serum at D1 and D30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative variations of lipopolysaccharides (LPS) in serum between day 1 and day 30</measure>
    <time_frame>1 month</time_frame>
    <description>Dosage of LPS in serum at D1 and D30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative variations of copeptin in serum between day 1 and day 30</measure>
    <time_frame>1 month</time_frame>
    <description>Dosage of copeptin in serum at D1 and D30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative variations of CRP in serum between day 1 and day 30</measure>
    <time_frame>1 month</time_frame>
    <description>Dosage of CRP in serum at D1 and D30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative variations of von Willebrand Factor antigen in serum between day 1 and day 30</measure>
    <time_frame>1 month</time_frame>
    <description>Dosage of von Willebrand Factor antigen in serum at D1 and D30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of the intestinal microbiota</measure>
    <time_frame>up to 18 months</time_frame>
    <description>analyzis of microbiota (quantity and quality of main bacterial strains) in 25 patients from arms A and B at day 1, and at months 3, 6, 12 and 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety analysis of the study drug</measure>
    <time_frame>12 months</time_frame>
    <description>Record of adverse events and serious adverse events in each arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Ascites</condition>
  <condition>Peritonitis</condition>
  <arm_group>
    <arm_group_label>Active rifaximin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifaximin placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>twice daily administration of 1 tablet containing 550 mg of active rifaximin</description>
    <arm_group_label>Active rifaximin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>twice daily administration of 1 rifaximin placebo tablet</description>
    <arm_group_label>Rifaximin placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhosis diagnosed on clinical, radiological and/or histological findings

          -  Patients with large ascites (i.e., grade 3 ascites requiring paracentesis).

          -  Ascites with a low protein level in ascitic fluid (&lt; 15 g/L) with:

               1. impaired renal function defined by serum creatinine ≥ 106 mmol/L, uremia ≥ 9
                  mmol/L or serum sodium ≤ 130 mmol/L), or

               2. severe liver impairment defined by Child-Pugh score ≥ 9 with serum total
                  bilirubin levels ≥ 51 mmol/L.

          -  Patient who signed an informed consent form

          -  Patient with a social security system

        Exclusion Criteria:

          -  Pregnant woman or breastfeeding

          -  Person under 18 years of age and over 80 years of age

          -  Transplanted patients, HIV infection (or patients who deny HIV serology) or
             immunosuppressive therapy

          -  Past SBP or any present bacterial infection

          -  Patient with a TIPS

          -  Patient receiving antibiotics (including rifaximin) in the month preceding the
             inclusion in this study

          -  Hypersensitivity to rifaximin, derivatives of rifamycin or one of the constituents of
             the preparation

          -  Hepatocellular carcinoma outside the Milan criteria, other cancer at a palliative
             stage,

          -  Gastrointestinal bleeding within 7 days

          -  Grade 3 hepatic encephalopathy (HE) during the screening phase or at randomization or
             previous grade 3 HE

          -  Chronic heart failure (stage III or IV of the New York Heart Association [NYHA]
             Functional Classification

          -  Patient judged as noncompliant

          -  Patients who cannot receive a clear information and who have no trusted relatives

          -  Patient who refuses the participation agreement by signing the information form and
             consent as defined in the protocol.

          -  Exclusion period from another biomedical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodolphe Anty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edouard Bardou-Jacquet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Bureau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent Di Martino, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Besançon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire Francoz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Beaujon, Clichy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandra Heurgue-Berlot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Reims</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne Latournerie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Dijon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre Louvet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Nahon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Jean Verdier, Bondy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frédéric Oberti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Angers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle Rosa-Hezode, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHIC de Créteil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marika Rudler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pitié-Salpêtrière, APHP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthieu Schnee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital La Roche-sur-Yon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thierry THEVENOT, MD, PhD</last_name>
    <phone>+33381668594</phone>
    <email>tthevenot@chu-besancon.fr</email>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary prophylaxis</keyword>
  <keyword>rifaximin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

